DNA Genotek Inc.
Search documents
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
Globenewswire· 2026-01-15 18:00
Core Viewpoint - OraSure Technologies, Inc. is facing a board election challenge as Altai Capital has nominated two candidates, including its founder Rishi Bajaj, for the Board of Directors at the upcoming 2026 Annual Meeting of Stockholders [1]. Group 1: Board Composition and Engagement - OraSure's Board has engaged extensively with Altai Capital, interviewing Mr. Bajaj for a potential board position but ultimately selecting an alternative candidate [2]. - The Board emphasizes its strong, independent, and engaged composition, having refreshed significantly since 2022 with seven directors departing and three new independent directors added, including healthcare investor Steven K. Boyd [3]. Group 2: Nominations and Proxy Statement - The Nominating and Corporate Governance Committee, along with OraSure's Board, will review Altai's nominations and will present their recommendations in a definitive proxy statement to be filed with the SEC [4]. - Shareholders are not required to take any action at this time regarding the nominations [4]. Group 3: Company Overview - OraSure Technologies, Inc. specializes in point-of-need and home diagnostic tests, aiming to improve healthcare access, quality, and value through innovative testing and sample management solutions [6]. - The company operates globally, providing products to various sectors including clinical laboratories, hospitals, and direct consumers [6].
OraSure Announces $40 Million Stock Repurchase Program
Newsfilter· 2025-03-24 11:30
Core Viewpoint - OraSure Technologies, Inc. has authorized a stock repurchase program of up to $40 million over the next twenty-four months, to be funded from cash on hand [1][2]. Company Overview - OraSure Technologies, Inc. is a leader in point-of-need and home diagnostic tests and sample management solutions, aiming to improve access, quality, and value of healthcare through innovative testing and sample management [3]. - The company, along with its subsidiaries DNA Genotek Inc. and Sherlock Biosciences, Inc., develops, manufactures, and distributes rapid diagnostic tests and sample collection devices globally [3]. Stock Repurchase Program - The stock repurchase may be executed through various methods in compliance with applicable laws, with the timing and amount determined at the management's discretion [2]. - The repurchase program can be modified, suspended, or discontinued at any time without prior notice [2].